Overview

SPI is focused on developing therapeutics to address patients with significant unmet medical needs in the space of sensorineural otologic diseases.

For additional details of SPI’s clinical trials, please follow the link to Clinicaltrials.gov

Our Product Pipeline

Indication
Therapeutic Candidate

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Meniere’s Disease
SPI-1005

(Phase 2)

Title

80%

Click for Status

Phase 2 Meniere’s Disease clinical trial completed with positive topline results

 

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Acute NIHL
Mild to Moderate
SPI-1005

(Phase 2)

Title

70%

Click for Status

SPI-1005 reduced the incidence and severity of NIHL,

published in The Lancet – July 2017

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Aminoglycoside-Induced Ototoxicity
SPI-3005

(Phase 1)

Title

70%

Click for Status

Phase 1b STOP Ototoxicity study completed,

see presentation at 2018 NACFC

A phase 2 study to test the safety and tolerability of SPI-1005 in people with cystic fibrosis is currently underway.  Details here.

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

COVID-19
SPI-1005

(Phase 1)

Title

50%

Click for Status

Study details for SPI-1005 Treatment in Severe COVID-19 Patients can be found here.

Study details for SPI-1005 Treatment in Moderate COVID-19 Patients can be found here.

Chemotherapy-Induced Ototoxicity
SPI-3005

(Phase 1)

Title

50%

Click for Status

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Severe to Profoundly
Impaired
SPI-5557

(Phase 1)

Title

20%

Click for Status

IND yet to be filed

Our Product Pipeline